Celgene’s blockbuster Revlimid fails in non-Hodgkin’s lymphoma DLBCL subtype

R2-CHOP failed to meet its primary endpoint of demonstrating superiority in progression-free survival (PFS) compared to R-CHOP.



  • Celgene DLBCL clinical trials